Strattera (correction)
Executive Summary
Lilly's attention deficit/hyperactivity disorder medication Strattera has been used in 3.4 mil. patients worldwide, the company says. "The Pink Sheet" (1Oct. 2, 2005, p. 8) incorrectly reported the figure as 2 mil. based on an FDA press release. Additionally, labeling for Shire's Adderall XR was inaccurately reported in the story. The amphetamine therapy carries a "black box" warning advising of drug dependence. A similar boxed warning is included under the Warnings section of Johnson & Johnson's Concerta...
You may also be interested in...
ADHD Suicidal Thinking Health Advisory Limited To Lilly’s Strattera
FDA does not intend to release a general public health advisory for attention deficit/hyperactivity disorder medications despite issuing one for Lilly's Strattera (atomoxetine) Sept. 29
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.